Maralixibat
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis
Conditions
Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
Trial Timeline
Sep 9, 2021 → Dec 17, 2024
NCT ID
NCT04729751About Maralixibat
Maralixibat is a phase 2 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04729751. Target conditions include Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04530994 | Pre-clinical | Completed |
| NCT07389031 | Phase 2 | Recruiting |
| NCT06553768 | Phase 3 | Recruiting |
| NCT04729751 | Phase 2 | Completed |
| NCT04524390 | Phase 2 | Completed |
| NCT04168385 | Phase 2 | Completed |
| NCT04185363 | Phase 3 | Completed |
| NCT03905330 | Phase 3 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis